Can Patients Off Jubbonti (Denosumab) Safely Undergo Dental Drilling?
Yes, patients who have discontinued denosumab can proceed with dental drilling procedures, but the timing and clinical context are critical—the risk of osteonecrosis of the jaw (ONJ) persists for months after stopping denosumab, though it decreases over time as the drug's effects reverse.
Understanding the ONJ Risk After Denosumab Discontinuation
The FDA label for Jubbonti explicitly states that ONJ can occur with denosumab therapy and is "generally associated with tooth extraction and/or local infection with delayed healing" 1. However, unlike bisphosphonates that remain deposited in bone for years, denosumab functions extracellularly and its effects on bone remodeling reverse within 9-24 months after the last dose 1, 2.
Key Timing Considerations:
- Bone turnover suppression: Returns to above pretreatment values at 9 months, then normalizes by 24 months after the last dose 1
- BMD returns: Bone mineral density returns to pretreatment values within 18 months 1
- ONJ healing cases: Multiple case reports document successful ONJ healing within 6-7 months after denosumab discontinuation 2, 3
Clinical Decision Algorithm
Step 1: Determine Time Since Last Denosumab Dose
If <6 months since last dose:
- ONJ risk remains elevated
- Defer elective drilling procedures if possible
- If urgent drilling needed, proceed with enhanced precautions (see below)
If 6-12 months since last dose:
- Risk is decreasing but still present
- Proceed with caution and enhanced monitoring
- Consider bone turnover markers if available
If >12-18 months since last dose:
- Drug effects largely reversed
- Risk approaches baseline
- Standard dental precautions apply
Step 2: Assess Individual Risk Factors
High-risk features that warrant extra caution 4, 1:
- Duration of prior denosumab therapy (>4 years increases risk)
- Poor oral hygiene or active periodontal disease
- Diabetes mellitus (uncontrolled)
- Concurrent corticosteroid use
- History of prior ONJ
- Smoking
- Concomitant chemotherapy or antiangiogenic agents
Step 3: Implement Protective Measures
Before the procedure:
- Optimize oral hygiene for 2-4 weeks prior
- Ensure adequate calcium and vitamin D supplementation 1
- Consider prophylactic antibiotics (amoxicillin or clindamycin) starting 1 day before
- Address any active infections first
During the procedure:
- Use minimally invasive techniques
- Preserve periosteum and blood supply 5, 6
- Ensure primary wound closure when possible
- Thoroughly remove any infected tissue
After the procedure:
- Continue antibiotics for 7-10 days
- Antimicrobial mouth rinses (chlorhexidine)
- Monitor healing every 2-4 weeks until complete mucosal coverage 7
- Watch for exposed bone, pain, or delayed healing
Critical Pitfalls to Avoid
Don't assume zero risk immediately after stopping: The reversible nature of denosumab is advantageous compared to bisphosphonates, but suppression persists for months 2, 3
Don't ignore the rebound phenomenon: Stopping denosumab without transition therapy causes rapid bone loss and increased fracture risk starting at 7 months 1. If the patient hasn't been transitioned to alternative therapy (bisphosphonate or other), coordinate with their prescribing physician.
Don't perform extensive surgery for established ONJ: If ONJ develops, conservative management (antibiotics, rinses, superficial debridement) is preferred initially; aggressive surgery may worsen the condition 7, 1
Special Considerations
For oncology patients (who typically receive higher doses—120mg monthly vs 60mg every 6 months for osteoporosis): The cumulative exposure is substantially higher, increasing ONJ risk 4, 8. These patients warrant longer waiting periods and more aggressive preventive measures.
If urgent dental work cannot be delayed: The NCCN guidelines state that "if invasive dental surgery is necessary, therapy should be deferred until the dentist confirms that the patient has healed completely from the dental procedure" 9. This principle applies in reverse—proceed with surgery but implement all protective measures and ensure close follow-up.
Guideline Divergence
There is notable disagreement about drug holidays: The American Dental Association does not recommend stopping bisphosphonates for dental procedures 4, while the American Association of Oral and Maxillofacial Surgeons recommends a 2-month holiday for patients on >4 years of bisphosphonates 4. For denosumab specifically, the MASCC/ISOO/ASCO guideline states there is "insufficient evidence to support or refute" temporary discontinuation before dental surgery 7. However, since your patient has already discontinued, this debate is moot—the question is whether enough time has passed.
The practical answer: drilling procedures can proceed in patients off denosumab, with timing and precautions scaled to individual risk factors and time since last dose.